Abstract
Introduction:
Successful embryo implantation, is the initiating step of pregnancy, relies on not only the high quality of the embryo but also the synergistic development of a healthy endometrium. Characterization and identification of biomarkers for the receptive endometrium is an effective method for increasing the probability of successful embryo implantation.
Methods:
Endometrial tissues from 22 women with a history of recurrent implantation failure (RIF) and 19 fertile controls were collected using biopsy catheters on 7-9 days after the peak of luteinizing hormone. Differentially expressed proteins (DEPs) were identified in six patients with RIF and six fertile controls using isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomics analysis.
Results:
Two hundred and sixty-three DEPs, including proteins with multiple bioactivities, such as protein translation, mitochondrial function, oxidoreductase activity, fatty acid and amino acid metabolism, were identified from iTRAQ. Four potential biomarkers for receptive endometrium named tubulin polymerization-promoting protein family member 3 TPPP3, S100 Calcium Binding Protein A13 (S100A13), 17b-hydroxysteroid dehydrogenase 2 (HSD17B2), and alpha-2-glycoprotein 1, zinc binding (AZGP1) were further verified using ProteinSimple Wes and immunohistochemical staining in all included samples (n=22 for RIF and n=19 for controls). Of the four proteins, the protein levels of TPPP3 and HSD17B2 were significantly downregulated in the endometrium of patients with RIF.
Discussion:
Poor endometrial receptivity is considered the main reason for the decrease in pregnancy success rates in patients suffering from RIF. iTRAQ techniques based on isotope markers can identify and quantify low abundance proteomics, and may be suitable for identifying differentially expressed proteins in RIF. This study provides novel evidence that TPPP3 and HSD17B2 may be effective targets for the diagnosis and treatment of non-receptive endometrium and RIF.
Introduction
Infertility is a common disease that troubles 10-15% couples of childbearing age globally (, ). In recent decades, the rapid development and application of assisted reproductive technology (ART) has provided the most effective methods for patients with infertility (). However, there are still approximately 10% of infertile women undergoing IVF and suffering repeated implantation failure (RIF), termed women who are under the age of 40 but fail to achieve clinical pregnancy after transferring at least four high-quality embryos in at least three fresh or frozen cycles (). Except for anatomical and chromosome abnormalities (such as uterine cavity abnormalities, hydrosalpinx and embryonic karyotype abnormalities), endometrial receptivity disorders are considered other contributor to RIF ().
During the menstrual cycle, the endometrium undergoes periodic changes in menstrual repair, proliferation, and secretory differentiation under the control of continuous and complex timing interactions of female sex hormones (). Endometrial receptivity refers to the maturation of the endometrium to support blastocyst acceptance and implantation, along with the endometrial epithelium and stromal cells, in a functional but transient state under the effects of ovarian estrogen and progesterone (). This period is also termed the window of implantation (WOI), which usually occurs 6-8 days after the peak of luteinizing hormone (LH) and lasts about 3-5 days. To date, there are numerous molecular mediators reported to be involved in the regulation of endometrial receptivity, including cytokines, lipids, adhesion molecules, and growth factors (such as cyclooxygenase-2, Krueppel-like factor 5, leukemia inhibitory factor, interleukins, insulin-like growth factor-binding proteins, wingless/integrated factor, prolactin (PRL), vascular endothelial growth factor, and homeobox A10) (–). In pathological conditions such as chronic or acute inflammation, this window narrows or shifts to preclude normal implantation of the embryo, resulting in infertility or loss of pregnancy (, ). Approximately 18.6%-30.6% of patients undergoing in vitro fertilization and embryo transfer (IVF-ET) experience WOI translocation, resulting in impaired endometrial receptivity, considered one of the main causes of pregnancy failure when transferring high-quality embryos (–).
Examinations of endometrial receptivity by different methods, including endometrial biopsies and imaging examinations (such as ultrasound), have paved the way for treating unexplained RIF in the past few years. Although ultrasound is widely used and non-invasive, it is empirical and difficult to unify the evaluation criteria, with a poor ability to predict pregnancy rates and strong subjectivity (). Since the 1920s, researchers have explored novel effective assessments of endometrial receptivity at the tissue level using endometrial microtubule structure (such as pinocytosis) and morphology (pinopodes), single molecule level by PRL, integrins, and multiple microarrays of -omics in recent years. In the past 20 years, microarrays (such as the endometrial receptivity array, ERA) and RNA sequencing techniques in whole-tissue transcriptional analysis have been widely used to assess endometrial receptivity and to determine the timing of IVF-ET (). A recent study used single-cell RNA sequencing to analyze the presence of endometrial cells at WOI in patients with RIF and healthy controls and provided detailed molecular and cellular patterns of healthy and RIF endometrium at WOI (). However, it is doubtful that techniques such as transcriptome-based ERA detection can improve the success rate of implantation ().
Proteins in the endometrium are considered the most direct functional molecule of an organism and the final effector of transcriptional gene translation. The change in functional proteins directly affects the exertion of individual biological functions. Several studies have focused on whether there are identifiable proteome counterparts for transcriptional features. To compare and quantify the total expression profiles of complex protein mixtures, previous studies have typically used two-dimensional differential in-gel electrophoresis(DIGE), Nanobore liquid chromatography-tandem mass spectrometry (LC-MS/MS), and MALDI-TOF-TOF techniques (–). Isobaric tag for relative and absolute quantitation (iTRAQ) is a widely used labeling quantitative proteome technology developed by Applied Biosystems Inc. (ABI) in 2004. It involves a set of molecules binding to N-terminal amino groups and free amino groups of lysine residues, thereby labeling the peptides and achieving the purpose of proteome comparison between different samples by labeling different source samples with reagents of different molecular weights (, ). However, most of the biomarkers screened by proteomics have not been further verified by traditional molecular biology methods. There is still a long way to go before applying these markers in clinical practice.
Therefore, we employ proteomics to identify the differentially expressed proteins that may trigger RIF. To compare proteins in multiple groups of samples qualitatively and quantitatively, we use iTRAQ labeling combined with LC-MS/MS techniques to screen differential WOI endometrial proteins and identify potential biomarkers in patients with RIF. In this study, ProteinSimple Wes and immunohistochemistry are used to verify the screened protein molecules, providing experimental data for the establishment of endometrial receptivity indicators and the diagnosis of RIF. Potent protein biomarkers are further confirmed in decidual and endometrial tissues from other published databases.
2 Materials and methods
2.1 Study population and study design
This study was evaluated and approved by the ethics committee of Shenzhen Zhongshan Urology Hospital (Approval number: SZZSECHU-20180023). The study included 41 females who visited the Fertility Center of Shenzhen Zhongshan Urology Hospital from January 2018 to December 2019. These patients included 22 females with a history of RIF who experienced failed pregnancy in the next period after endometrial scratch and 19 fertile females who retrieved successful pregnancy in the next period after endometrial scratch. Herein, RIF was defined as women who experienced two or more retrieval cycles and transferred more than ten high-quality embryos without pregnancy (). Among these patients, endometria from six RIF patients and six controls were subjected to proteomics analysis using isobaric tags for relative and absolute quantification (iTRAQ). All included patients were recruited for the validation of key deferentially expressed proteins (DEPs). Table 1 presents the baseline characteristics of the study population.
Table 1
| 1a. Population for iTRAQ analysis | |||
|---|---|---|---|
| Group | Normal pregnancy (n = 6) | Repeated implantation failure (n = 6) | p-value |
| Age (years) | 33.2 ± 3.8 | 34.7 ± 5.8 | 0.61 |
| BMI (kg/m2) | 21.7 ± 2.0 | 20.2 ± 2.5 | 0.27 |
| E2 (pg/mL) | 30.0 ± 17.4 | 38.1 ± 20.0 | 0.47 |
| P (ng/mL) | 0.7 ± 1.1 | 0.4 ± 0.2 | 0.58 |
| FSH (IU/L) | 6.3 ± 1.9 | 8.4 ± 2.8 | 0.15 |
| AMH (ng/mL) | 2.8 ± 0.9 | 1.9 ± 0.7 | 0.14 |
| LH (IU/L) | 6.5 ± 4.2 | 3.8 ± 1.8 | 0.17 |
| PRL (ng/mL) | 18.8 ± 4.2 | 15.8 ± 7.8 | 0.47 |
| T (ng/mL) | 0.2 ± 0.1 | 0.2 ± 0.2 | 0.47 |
| Endometrial thickness (mm) | 9.8 ± 0.8 | 9.2 ± 1.4 | 0.34 |
| 1b. Population for validation | |||
| Group | Normal pregnancy (n = 19) | Repeated implantation failure (n = 22) | p-value |
| Age (years) | 33.2 ± 4.1 | 33.5 ± 4.2 | 0.82 |
| BMI (kg/m2) | 21.4 ± 2.3 | 21.2 ± 2.3 | 0.81 |
| E2 (pg/mL) | 39.0 ± 39.6 | 43.5 ± 41.8 | 0.74 |
| P (ng/mL) | 0.4 ± 0.6 | 0.5 ± 0.3 | 0.83 |
| FSH (IU/L) | 5.5 ± 1.7 | 6.6 ± 1.5 | 0.05 |
| AMH (ng/mL) | 2.8 ± 1.3 | 2.3 ± 1.3 | 0.30 |
| LH (IU/L) | 4.0 ± 3.2 | 4.0 ± 1.6 | 0.94 |
| PRL (ng/mL) | 16.6 ± 7.0 | 17.4 ± 7.5 | 0.77 |
| T (ng/mL) | 0.3 ± 0.2 | 0.3 ± 0.2 | 0.98 |
| Endometrial thickness (mm) | 10.3 ± 2.1 | 9.7 ± 2.0 | 0.31 |
Baseline characteristics of the study population.
2.2 Endometrial preparation program and sample collection
Natural cycles were used for the included patients before collecting the endometrium. During the cycles, progesterone (Dydrogesterone Tablet, Solvay Pharmaceuticals, Netherlands) was commenced at a dose of 20 mg per day for 18 days of the cycle and continued until the mid-luteal phase of the menstrual cycle. The endometrial tissues were collected by biopsy catheter (Gynetics, Lommel, Belgium) after 7-9 days of LH surge (LH 7-9) of the natural menstrual cycle before controlled ovarian hyperstimulation, which is confirmed by ultrasound monitoring of ovulation (). Endometrial tissues were divided into two parts. One part was frozen at -80°C for iTRAQ or ProteinSimple Wes analysis. The other part was fixed in 4% formaldehyde for immunohistochemical (IHC) staining.
2.3 Measurements of serum hormone levels
On day 3 of the menstrual cycle, the concentrations of estradiol (E2), progesterone (P), follicle-stimulating hormone (FSH), anti-muellerian hormone (AMH), luteinizing hormone (LH), prolactin (PRL), and testosterone (T) in the sera of the patients were measured with Elecsys Estradiol III, progesterone II, FSH, AMH, LH, Prolactin II, and Testosterone II kit (Elecsys, Olathe, USA) and analyzed in an immunology analyzer (Roche Diagnostics, Basel, Switzerland).
2.4 iTRAQ-based proteomics analysis
Protein sample preparation, iTRAQ labeling, and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based protein identification were accomplished by FitGene Biotechnology Company (Guangzhou, China). Tissues were briefly lysed and sonicated for protein collection. Protein concentration was determined using the Bradford method. 8-plex iTRAQ labeling was performed following the manufacturer’s protocol (AB Scienx). Labeled peptides were fractionated, followed by LC-MS/MS analysis.
2.5 Biological analysis
iTRAQ experiments generate large datasets. Initially, MS-based proteomics was used to identify and quantify the proteins present in each sample. The original data from MS-based proteomics were analyzed using the ProteinPilot software to obtain reliable proteins. The analysis process was described as follows: DEPs screening was conducted based on the following inclusion criteria: (1) After the retrieval was completed, examining the Unused value for the original retrieval results, and setting Unused ≥ 1.3, so that the reliability of the protein was above 95%. (2) Removing the records beginning with “RRRR” and the reverse database from the search results. ProteinPilot™ performed false discovery rate (FDR) analysis to evaluate the accuracy of the retrieval results. The FDR analysis was realized by reverse library retrieval. Subsequently, DEPs were selected based on the following inclusion criteria: (1) coefficient of variation<0.5; (2) p-value<0.05 (t-test); (3) fold change ≥ 1.2 or ≤ 0.83. The detailed values (unused, citable accession, gene name, fold change, and p-value) for DEPs, including 15 proteins (fold change > 1.5 or < 0.67) are listed in Supplementary Table 2. The R package pheatmap, a free online platform (http://www.bioinformatics.com.cn), was used to visualize the DEPs, shown as volcano and heat maps ().
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed based on the DEPs. The bubble charts of GO terms were plotted by an online platform (http://www.bioinformatics.com.cn), whereas the chord diagrams of KEGG pathways were visualized by the clusterProfiler package. Furthermore, the protein-protein interaction (PPI) networks predicted by STRING (https://string-db.org/cgi/input.pl) were further visualized in Cytoscape software (version 3.8.2). The top ten hub proteins were identified from the PPI network of proteins through the calculation of degrees algorithm, and their expression levels were revealed in a heat map ().
Key proteins were further investigated according to fold change, biological function, and top enriched GO terms and KEGG pathways. The screening process is shown in Figure 1A, and the expression levels of key proteins are shown in a heat map. Key proteins including TPPP3 and HSD17B2 were further reviewed in published literature and the Human Protein Atlas (https://www.proteinatlas.org/). The expression levels of TPPP3 and HSD17B2 in decidual tissues were obtained from the research by Yu et al. (). The immunoreactive pattern of TPPP3 and HSD17B2 in the endometrium were further contrasted with immunohistochemistry images for those antigens in endometrial sections available in the Human Protein Atlas database.
Figure 1
2.6 Immunohistochemistry
Specifically, the samples were fixed and embedded in paraffin for IHC staining. Using Bond polymer refine detection kit (Leica Microsystems, Germany), the samples were stained in an automatic immunostaining machine (Leica Bond Rx system, Germany). The images were collected by the multispectral panoramic tissue program analysis system Panel Detection 1.0 (Panovue, Beijing, China) and visualized by the HALO digital pathological image analysis platform (lndica Labs, USA). Detailed information regarding the primary antibodies used is provided in Supplementary Table 1.
2.7 ProteinSimple Wes analysis
Endometrial tissues were lysed with Radio Immunoprecipitation Assay (RIPA) Lysis Buffer (Beyotime, Shanghai, China), and the lysates were centrifuged 12000 × g for 15 min at 4°C to collect the supernatant. The BCA assay kit (Beyotime, Shanghai, China), was used to quantify the concentrations of total proteins. An automated Wes Capillary System (Protein Simple, San Jose, CA, 12-230 kDa kit cat. SM-W004) was used to detect the protein levels. Total protein loading was at a concentration of 1 μg/μL for each sample. Immunoblot analysis was executed using the Compass for Simple Western Program (ProteinSimple Wes, USA). More detailed information about primary antibodies is presented in Supplementary Table 1.
2.8 Statistical analysis
Statistical analyses were performed using SPSS for Windows (version 25.0, SPSS Inc., Chicago, IL). Variables were analyzed by student’s t-test, and shown as mean ± standard deviation. In all comparisons, a two-tailed p-value < 0.05 was considered statistically significant.
3 Results
3.1 Baseline characteristics of the study population
Baseline characteristics, including maternal age, body mass index (BMI), baseline serum hormone levels (E2, P, FSH, AMH, LH, PRL and T), and endometrial thickness were comparable between the RIF group and the fertile controls (Table 1, p ≥ 0.05 for each parameter). Table 1 presents the baseline characteristics of the study population.
3.2 Functional enrichment analysis and protein-protein interaction network analysis of DEPs
Totally, there were 263 DEPs identified in the endometrial tissues of RIF patients compared with those from fertile controls, including 202 down-regulated proteins and 61 up-regulated proteins (Figure 2A; Supplementary Table 2). These DEPs were expressed at exactly opposite levels between RIF and control group (Figure 2B). GO term enrichment showed that DEPs were primarily enriched in translation, ribosomal subunits, carboxylic acid metabolic processes, oxidoreductase activity, and mitochondrial function (Figure 3A). KEGG pathways were mainly enriched in ribosome, immune response, and metabolism, including fatty acid, amino acid, carbon, and other organic acid metabolism. (Figure 3B). The top ten hub proteins were ribosomal proteins, including RPL5, RPL23A, RPL23, RPL27, RPS3A, RPS6, RPS8, RPS12, RPS18 and RPS24 (Figure 4). These hub proteins were all down-regulated in the endometria of patients with RIF, suggesting that deficiency of ribosomal protein small subunit (RPS) and ribosomal protein large subunit (RPL) may be associated with impaired endometrial receptivity.
Figure 2
Figure 3
Figure 4
3.3 Validation of key proteins
Key proteins were further screened according to fold change (> 1.5 or < 0.67), biological functions (cell proliferation or apoptosis, immune response, or angiogenesis), and top-enriched GO terms and KEGG pathways. The screening process is shown in Figure 1A. iTRAQ analysis showed that the expressions of HSD17B2 and AZGP1 decreased in the endometria from RIF patients compared with those from fertile controls, whereas TPPP3, APEX1, and S100A13 increased in the RIF group (Figure 1B). Both ProteinSimple Wes analysis and IHC staining verified the down-regulation of HSD17B2, AZGP1, TPPP3, and S100A13 in the endometrial tissues of the RIF patients compared to those from the fertile controls (Figures 5A, B, 6). Interestingly, the expression levels of TPPP3 and HSD17B2 also decreased in the decidual tissues of patients with miscarriage (Figures 7A, E). These two proteins were further examined in the Human Protein Atlas. The signals of TPPP3 were primarily located in the cell nucleus and expressed in the endometrial ciliated cells (Figures 7B–D). The signals of HSD17B2 were mostly located in endoplasmic reticulum and expressed in glandular and luminal cells (Figures 7F–H).
Figure 5
Figure 6
Figure 7
Discussion
Although ART has made rapid progress in the past 40 years, the clinical pregnancy rate and live birth rate of ART remain at only 54.7% and 45.0%, respectively (
Recently, researchers sought to evaluating whole genome and transcriptome through ERA or RNA-seq in the endometria from RIF to identify the abnormal interruptions in endometrial receptivity gene expression profiles (
In this study, iTRAQ LC-MS/MS was employed to screen specific proteins related to endometrial receptivity. We detected more than 5000 proteins in each iTRAQ experiment, and screened 263 DEPs after three parallel experiments. Among all the DEPs identified in this study, the central protein of the protein interaction network is ribosomal proteins, including RPL and RPS. Our data showed that both RPL and RPS are down-regulated in the endometria from patients with RIF, suggesting that defects in ribosomal subunits may lead to failed embryo implantation by impairing endometrial receptivity. Simultaneously, DEPs were primarily enriched in the translation, ribosomal subunits and synthesis of GO biology, and the results from KEGG pathway analysis also echo this observation. Moreover, GO molecular functional association network and KEGG pathway analysis indicated that DEPs were primarily rich in carboxylic acid metabolism, oxidoreductase activity and mitochondrial function, and active in immune response and metabolic pathways, including fatty acid, amino acid, carbon metabolism, and other organic acid metabolism. This suggests that the mechanism of altering cell metabolism may be closely related to the disturbance of endometrial receptivity. Material metabolism and mitochondrial function are very important for embryo implantation and pregnancy. Studies have shown that the samples from patients with RIF exhibit obvious mitochondrial dysfunction characteristics, and biological metabolic processes, such as hormones and lipids, also differ significantly from samples from patients with normal pregnancy (
The key functional proteins according to the multiple changes were further enriched in GO terms and KEGG pathway. ITRAQ analysis showed that compared with the fertile control, the protein levels of HSD17B2 and AZGP1 in the endometria from RIF were down-regulated, whereas the expression of TPPP3, APEX1, and S100A13 were up-regulated. These proteins are primarily involved in biological processes such as cell proliferation and apoptosis, immune response or angiogenesis, which play important roles in the process of embryo implantation. Consequently, we expanded the sample size and further verified the expression of these five key proteins by Protein Simple Wes and IHC staining. The results showed that the protein levels of HSD17B2, AZGP1, TPPP3, and S100A13 in endometrium of RIF patients were significantly lower than patients with normal pregnancy.
TPPP3 is a member of the tubulin polymerization promoting protein family, which can bind to tubulin, promote microtubule aggregation, and maintain the stability and integrity of the microtubule system (
S100A13 is a small calcium (Ca2+)-binding protein belonging to the S100 family. S100 proteins play fundamental roles in a series of cellular processes, such as calcium homeostasis, cell proliferation, apoptosis, and inflammation (
HSD17B is an enzyme responsible for the synthesis and inactivation of estrogen and androgen. In addition to producing active progesterone, HSD17B2 oxidizes estradiol to estrone and testosterone and androstenediol to androstenedione dehydroepiandrosterone (
AZGP1, also known as zinc- α 2-glycoprotein (ZAG), is a secretory adipose factor regulated by thyroid hormones, androgens, and glucocorticoids (
We re-analyzed the data from a recurrent abortion DNA methylome and transcriptome from Yu et al., (
Although this study may provide new targets for the diagnosis and treatment of RIF, it has some limitations. First, the sample size of this study is inadequate, and some unknown bias may exist. This may also be the main reason for the inconsistent expression trend of two key proteins, TPPP3 and S100A13, in specimen verification and proteomics analysis. To avoid the deviation caused by individual heterogeneity, large sample sizes may be required to further verify the findings. Second, proteomic specimens are obtained by invasive endometrial biopsy, whether DEPs including TPPP3 and HSD17B2 are useful as an important reference for endometrial receptivity in non-invasive acquisition of samples of blood, urine and cervical swabs needed to be verified in the coming study. Finally, the molecular mechanism and treatment strategies of the key proteins including TPPP3 and HSD17B2 should be further verified in animal studies.
In summary, our results suggest that endometrial TPPP3, S100A13, HSD17B2, and AZGP1 levels may be key biochemical markers for endometrial receptivity and the diagnosis of RIF. Our results provide novel experimental evidences for the establishment of endometrial receptivity indicators and a new outlook for the pathogenesis of poor endometrial receptivity in patients with RIF.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://ngdc.cncb.ac.cn, PRJCA014430.
Ethics statement
The studies involving human participants were reviewed and approved by the ethics committee of Shenzhen Zhongshan Urology Hospital (Approval number: SZZSECHU-20180023). The patients/participants provided their written informed consent to participate in this study.
Author contributions
JY (1st author), LW, and LL conceived the original idea and the structure of the manuscript. LW and JM performed the statistical analysis. JY (1st author) and LW drafted the first version of the manuscript. JY (1st author), LW, and JM developed the figures. LD and JC provided critical feedback and helped shape the manuscript. LL, JY (7th author), and YC supervised and revised the manuscript. All authors contributed to the article and approved the submitted version.
Funding
The present study is financially supported by Guangdong Basic and Applied Basic Research Foundation (2022A1515010850) and Basic Research Program of Shenzhen (JCYJ20190813161010761).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2023.1144393/full#supplementary-material
References
1
CarsonSAKallenAN. Diagnosis and management of infertility: A review. JAMA (2021) 326(1):65–76. doi: 10.1001/jama.2021.4788
2
BreitkopfDMHillM. Infertility workup for the women's health specialist: acog committee opinion, number 781. Obstet Gynecol (2019) 133(6):e377–e84. doi: 10.1097/AOG.0000000000003271
3
KushnirVABaradDHAlbertiniDFDarmonSKGleicherN. Systematic review of worldwide trends in assisted reproductive technology 2004-2013. Reprod Biol Endocrinol (2017) 15(1):6. doi: 10.1186/s12958-016-0225-2
4
CoughlanCLedgerWWangQLiuFDemirolAGurganTet al. Recurrent implantation failure: definition and management. Reprod BioMed Online (2014) 28(1):14–38. doi: 10.1016/j.rbmo.2013.08.011
5
CimadomoDCraciunasLVermeulenNVomsteinKTothB. Definition, diagnostic and therapeutic options in recurrent implantation failure: an international survey of clinicians and embryologists. Hum Reprod (2021) 36(2):305–17. doi: 10.1093/humrep/deaa317
6
WangWVilellaFAlamaPMorenoIMignardiMIsakovaAet al. Single-cell transcriptomic atlas of the human endometrium during the menstrual cycle. Nat Med (2020) 26(10):1644–53. doi: 10.1038/s41591-020-1040-z
7
LesseyBAYoungSL. What exactly is endometrial receptivity? Fertil Steril (2019) 111(4):611–7. doi: 10.1016/j.fertnstert.2019.02.009
8
YangTZhaoJLiuFLiY. Lipid metabolism and endometrial receptivity. Hum Reprod Update (2022) 28(6):858–89. doi: 10.1093/humupd/dmac026
9
CraciunasLGallosIChuJBourneTQuenbySBrosensJJet al. Conventional and modern markers of endometrial receptivity: A systematic review and meta-analysis. Hum Reprod Update (2019) 25(2):202–23. doi: 10.1093/humupd/dmy044
10
AchacheHRevelA. Endometrial receptivity markers, the journey to successful embryo implantation. Hum Reprod Update (2006) 12(6):731–46. doi: 10.1093/humupd/dml004
11
SinghMChaudhryPAsselinE. Bridging endometrial receptivity and implantation: network of hormones, cytokines, and growth factors. J Endocrinol (2011) 210(1):5–14. doi: 10.1530/JOE-10-0461
12
SalmasiSSharifiMRashidiB. Evaluating the effect of ovarian stimulation and exogenous progesterone on cd31-positive cell density, vegf protein, and mir-17-5p expression of endometrium immediately before implantation. BioMed Pharmacother (2021) 133:110922. doi: 10.1016/j.biopha.2020.110922
13
SzczepanskaMWirstleinPLuczakMJagodzinskiPPSkrzypczakJ. Reduced expression of hoxa10 in the midluteal endometrium from infertile women with minimal endometriosis. BioMed Pharmacother (2010) 64(10):697–705. doi: 10.1016/j.biopha.2010.09.012
14
AdamczykMRawluszko-WieczorekAAWirstleinPNowickiMJagodzinskiPPWender-OzegowskaEet al. Assessment of tet1 gene expression, DNA methylation and H3k27me3 level of its promoter region in eutopic endometrium of women with endometriosis and infertility. BioMed Pharmacother (2022) 150:112989. doi: 10.1016/j.biopha.2022.112989
15
Ruiz-AlonsoMBlesaDDiaz-GimenoPGomezEFernandez-SanchezMCarranzaFet al. The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure. Fertil Steril (2013) 100(3):818–24. doi: 10.1016/j.fertnstert.2013.05.004
16
Sebastian-LeonPGarridoNRemohiJPellicerADiaz-GimenoP. Asynchronous and pathological windows of implantation: two causes of recurrent implantation failure. Hum Reprod (2018) 33(4):626–35. doi: 10.1093/humrep/dey023
17
ChenJHeAZhangQZhaoJFuJLiHet al. The rna-seq based endometrial receptivity test (Rsert) compared to pinopode: A better diagnostic tool for endometrial receptivity for patients with recurrent implantation failure in chinese population. Front Endocrinol (Lausanne) (2022) 13:1009161. doi: 10.3389/fendo.2022.1009161
18
GallianoDBellverJDiaz-GarciaCSimonCPellicerA. Art and uterine pathology: how relevant is the maternal side for implantation? Hum Reprod Update (2015) 21(1):13–38. doi: 10.1093/humupd/dmu047
19
HeAZouYWanCZhaoJZhangQYaoZet al. The role of transcriptomic biomarkers of endometrial receptivity in personalized embryo transfer for patients with repeated implantation failure. J Transl Med (2021) 19(1):176. doi: 10.1186/s12967-021-02837-y
20
ChenZWangZDuMLiuZ. Artificial intelligence in the assessment of female reproductive function using ultrasound: A review. J Ultrasound Med (2022) 41(6):1343–53. doi: 10.1002/jum.15827
21
MaziotisEKalampokasTGiannelouPGrigoriadisSRapaniAAnifantakisMet al. Commercially available molecular approaches to evaluate endometrial receptivity: A systematic review and critical analysis of the literature. Diagnostics (Basel) (2022) 12(11):2611. doi: 10.3390/diagnostics12112611
22
LaiZZWangYZhouWJLiangZShiJWYangHLet al. Single-cell transcriptome profiling of the human endometrium of patients with recurrent implantation failure. Theranostics (2022) 12(15):6527–47. doi: 10.7150/thno.74053
23
ArianSEHessamiKKhatibiAToAKShamshirsazAAGibbonsW. Endometrial receptivity array before frozen embryo transfer cycles: A systematic review and meta-analysis. Fertil Steril (2022) 119(2):229–238. doi: 10.1016/j.fertnstert.2022.11.012
24
Garrido-GomezTQuinoneroAAntunezODiaz-GimenoPBellverJSimonCet al. Deciphering the proteomic signature of human endometrial receptivity. Hum Reprod (2014) 29(9):1957–67. doi: 10.1093/humrep/deu171
25
BissonnetteLDrissennekLAntoineYTiersLHirtzCLehmannSet al. Human S100a10 plays a crucial role in the acquisition of the endometrial receptivity phenotype. Cell Adh Migr (2016) 10(3):282–98. doi: 10.1080/19336918.2015.1128623
26
BielfeldAPPourSJPoschmannGStuhlerKKrusselJSBaston-BustDM. A proteome approach reveals differences between fertile women and patients with repeated implantation failure on endometrial level(-)Does hcg render the endometrium of rif patients? Int J Mol Sci (2019) 20(2):425. doi: 10.3390/ijms20020425
27
RossPLHuangYNMarcheseJNWilliamsonBParkerKHattanSet al. Multiplexed protein quantitation in saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics (2004) 3(12):1154–69. doi: 10.1074/mcp.M400129-MCP200
28
ChenXSunYZhangTShuLRoepstorffPYangF. Quantitative proteomics using isobaric labeling: A practical guide. Genomics Proteomics Bioinf (2021) 19(5):689–706. doi: 10.1016/j.gpb.2021.08.012
29
WangLLiLLiYHuangCLianRWuTet al. A history of endometriosis is associated with decreased peripheral Nk cytotoxicity and increased infiltration of uterine cd68(+) macrophages. Front Immunol (2021) 12:711231. doi: 10.3389/fimmu.2021.711231
30
DiaoLCaiSHuangCLiLYuSWangLet al. New endometrial immune cell-based score (Ei-score) for the prediction of implantation success for patients undergoing Ivf/Icsi. Placenta (2020) 99:180–8. doi: 10.1016/j.placenta.2020.07.025
31
DengZMDaiFFZhouQChengYX. Hsa_Circ_0000301 facilitates the progression of cervical cancer by targeting mir-1228-3p/irf4 axis. BMC Cancer (2021) 21(1):583. doi: 10.1186/s12885-021-08331-4
32
WangLDengZYangJZhaoYZhouLDiaoLet al. Epigenetic and transcriptomic characterization of maternal-fetal interface in patients with recurrent miscarriage via an integrated multi-omics approach. J Reprod Immunol (2022) 154:103754. doi: 10.1016/j.jri.2022.103754
33
YuMDuGXuQHuangZHuangXQinYet al. Integrated analysis of DNA methylome and transcriptome identified creb5 as a novel risk gene contributing to recurrent pregnancy loss. EBioMedicine (2018) 35:334–44. doi: 10.1016/j.ebiom.2018.07.042
34
SunderamSKissinDMZhangYJewettABouletSLWarnerLet al. Assisted reproductive technology surveillance - United States, 2018. MMWR Surveill Summ (2022) 71(4):1–19. doi: 10.15585/mmwr.ss7104a1
35
MrozikiewiczAEOzarowskiMJedrzejczakP. Biomolecular markers of recurrent implantation failure-a review. Int J Mol Sci (2021) 22(18):10082. doi: 10.3390/ijms221810082
36
BusnelliAReschiniMCardellicchioLVegettiWSomiglianaEVercelliniP. How common is real repeated implantation failure? An indirect estimate of the prevalence. Reprod BioMed Online (2020) 40(1):91–7. doi: 10.1016/j.rbmo.2019.10.014
37
HorcajadasJAPellicerASimonC. Wide genomic analysis of human endometrial receptivity: new times, new opportunities. Hum Reprod Update (2007) 13(1):77–86. doi: 10.1093/humupd/dml046
38
KootYEvan HooffSRBoomsmaCMvan LeenenDGroot KoerkampMJGoddijnMet al. An endometrial gene expression signature accurately predicts recurrent implantation failure after Ivf. Sci Rep (2016) 6:19411. doi: 10.1038/srep19411
39
BastuEDemiralIGunelTUlgenEGumusogluEHosseiniMKet al. Potential marker pathways in the endometrium that may cause recurrent implantation failure. Reprod Sci (2019) 26(7):879–90. doi: 10.1177/1933719118792104
40
StephensANHannanNJRainczukAMeehanKLChenJNichollsPKet al. Post-translational modifications and protein-specific isoforms in endometriosis revealed by 2d dige. J Proteome Res (2010) 9(5):2438–49. doi: 10.1021/pr901131p
41
HaouziDDechaudHAssouSDe VosJHamamahS. Insights into human endometrial receptivity from transcriptomic and proteomic data. Reprod BioMed Online (2012) 24(1):23–34. doi: 10.1016/j.rbmo.2011.09.009
42
Perez-DebenSBellverJAlamaPSalsanoSQuinoneroASebastian-LeonPet al. Itraq comparison of proteomic profiles of endometrial receptivity. J Proteomics (2019) 203:103381. doi: 10.1016/j.jprot.2019.103381
43
WangCFengYZhouWJChengZJJiangMYZhouYet al. Screening and identification of endometrial proteins as novel potential biomarkers for repeated implantation failure. PeerJ (2021) 9:e11009. doi: 10.7717/peerj.11009
44
Devesa-PeiroASebastian-LeonPGarcia-GarciaFArnauVAlemanAPellicerAet al. Uterine disorders affecting female fertility: what are the molecular functions altered in endometrium? Fertil Steril (2020) 113(6):1261–74. doi: 10.1016/j.fertnstert.2020.01.025
45
LaiZZZhangJZhouWJShiJWYangHLYangSLet al. Identification of potential biomarkers and immune infiltration characteristics in recurrent implantation failure using bioinformatics analysis. Front Immunol (2023) 14:992765. doi: 10.3389/fimmu.2023.992765
46
WangZNieKSuHTangYWangHXuXet al. Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome. Phytomedicine (2021) 91:153654. doi: 10.1016/j.phymed.2021.153654
47
MonsivaisDNagashimaTPrunskaite-HyyrylainenRNozawaKShimadaKTangSet al. Endometrial receptivity and implantation require uterine bmp signaling through an Acvr2a-Smad1/Smad5 axis. Nat Commun (2021) 12(1):3386. doi: 10.1038/s41467-021-23571-5
48
ZhangHQiJWangYSunJLiZSuiLet al. Progesterone regulates glucose metabolism through glucose transporter 1 to promote endometrial receptivity. Front Physiol (2020) 11:543148. doi: 10.3389/fphys.2020.543148
49
VinczeOTokesiNOlahJHlavandaEZotterAHorvathIet al. Tubulin polymerization promoting proteins (Tppps): members of a new family with distinct structures and functions. Biochemistry (2006) 45(46):13818–26. doi: 10.1021/bi061305e
50
XiaoTLinFZhouJTangZ. The expression and role of tubulin polymerization-promoting protein 3 in oral squamous cell carcinoma. Arch Oral Biol (2022) 143:105519. doi: 10.1016/j.archoralbio.2022.105519
51
SuQYangZGuoXMoWLiX. Tubulin polymerization promoting protein family member 3 (Tppp3) overexpression inhibits cell proliferation and invasion in nasopharyngeal carcinoma. Bioengineered (2021) 12(1):8485–95. doi: 10.1080/21655979.2021.1984006
52
ShenATongXLiHChuLJinXMaHet al. Tppp3 inhibits the proliferation, invasion and migration of endometrial carcinoma targeted with mir-1827. Clin Exp Pharmacol Physiol (2021) 48(6):890–901. doi: 10.1111/1440-1681.13456
53
ChuMWanHZhangX. Requirement of splicing factor hnrnp A2b1 for tumorigenesis of melanoma stem cells. Stem Cell Res Ther (2021) 12(1):90. doi: 10.1186/s13287-020-02124-5
54
ZhangXShiMZhaoXBinEHuYTangNet al. Telomere shortening impairs alveolar regeneration. Cell Prolif (2022) 55(4):e13211. doi: 10.1111/cpr.13211
55
OlahJLehotzkyASzenasiTBerkiTOvadiJ. Modulatory role of Tppp3 in microtubule organization and its impact on alpha-synuclein pathology. Cells (2022) 11(19):3025. doi: 10.3390/cells11193025
56
LiuNLiYNanWZhouWHuangJLiRet al. Interaction of tppp3 with vdac1 promotes endothelial injury through activation of reactive oxygen species. Oxid Med Cell Longev (2020) 2020:5950195. doi: 10.1155/2020/5950195
57
ShuklaVPopliPKaushalJBGuptaKDwivediA. Uterine Tppp3 plays important role in embryo implantation via modulation of beta-catenin. Biol Reprod (2018) 99(5):982–99. doi: 10.1093/biolre/ioy136
58
ShuklaVKaushalJBSankhwarPManoharMDwivediA. Inhibition of Tppp3 attenuates Beta-Catenin/Nf-Kappab/Cox-2 signaling in endometrial stromal cells and impairs decidualization. J Endocrinol (2019) 240(3):417–29. doi: 10.1530/JOE-18-0459
59
LiRLiWHeFZhangMLuoHTangH. Systematic screening identifies a Tead4-S100a13 axis modulating cisplatin sensitivity of oral squamous cell carcinoma cells. J Oral Pathol Med (2021) 50(9):882–90. doi: 10.1111/jop.13224
60
ShaoHGeMZhangJZhaoTZhangS. Osteoclasts differential-related prognostic biomarker for osteosarcoma based on single cell, bulk cell and gene expression datasets. BMC Cancer (2022) 22(1):288. doi: 10.1186/s12885-022-09380-z
61
ZhangYYangXZhuXLBaiHWangZZZhangJJet al. S100a gene family: immune-related prognostic biomarkers and therapeutic targets for low-grade glioma. Aging (Albany NY) (2021) 13(11):15459–78. doi: 10.18632/aging.203103
62
SalehMChandrashekarDSShahinSAgarwalSKimHGBehringMet al. Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian women. Transl Oncol (2021) 14(7):101086. doi: 10.1016/j.tranon.2021.101086
63
ChoiYKimHRLimEJParkMYoonJAKimYSet al. Integrative analyses of uterine transcriptome and micrornaome reveal compromised lif-stat3 signaling and progesterone response in the endometrium of patients with recurrent/repeated implantation failure (Rif). PloS One (2016) 11(6):e0157696. doi: 10.1371/journal.pone.0157696
64
Hernandez-VargasPMunozMDominguezF. Identifying biomarkers for predicting successful embryo implantation: applying single to multi-omics to improve reproductive outcomes. Hum Reprod Update (2020) 26(2):264–301. doi: 10.1093/humupd/dmz042
65
KoelMKrjutskovKSaareMSamuelKLubenetsDKatayamaSet al. Human endometrial cell-type-specific rna sequencing provides new insights into the embryo-endometrium interplay. Hum Reprod Open (2022) 2022(4):hoac043. doi: 10.1093/hropen/hoac043
66
WangBShaoY. Annexin A2 acts as an adherent molecule under the regulation of steroids during embryo implantation. Mol Hum Reprod (2020) 26(11):825–36. doi: 10.1093/molehr/gaaa065
67
LiuXMDingGLJiangYPanHJZhangDWangTTet al. Down-regulation of S100a11, a calcium-binding protein, in human endometrium may cause reproductive failure. J Clin Endocrinol Metab (2012) 97(10):3672–83. doi: 10.1210/jc.2012-2075
68
DuncanKA. Estrogen formation and inactivation following tbi: what we know and where we could go. Front Endocrinol (Lausanne) (2020) 11:345. doi: 10.3389/fendo.2020.00345
69
HilbornEStalOJanssonA. Estrogen and androgen-converting enzymes 17beta-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17beta-hydroxysteroid dehydrogenase type 1, 2, and breast cancer. Oncotarget (2017) 8(18):30552–62. doi: 10.18632/oncotarget.15547
70
SaloniemiTJokelaHStraussLPakarinenPPoutanenM. The diversity of sex steroid action: novel functions of hydroxysteroid (17beta) dehydrogenases as revealed by genetically modified mouse models. J Endocrinol (2012) 212(1):27–40. doi: 10.1530/JOE-11-0315
71
SoubhyeJAlardICvan AntwerpenPDufrasneF. Type 2 17-beta hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis. Future Med Chem (2015) 7(11):1431–56. doi: 10.4155/fmc.15.74
72
Wu-WongJRLiXChenYW. Different vitamin D receptor agonists exhibit differential effects on endothelial function and aortic gene expression in 5/6 nephrectomized rats. J Steroid Biochem Mol Biol (2015) 148:202–9. doi: 10.1016/j.jsbmb.2014.12.002
73
OlsonSHBanderaEVOrlowI. Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: A huge review. Am J Epidemiol (2007) 165(3):235–45. doi: 10.1093/aje/kwk015
74
BulunSEChengYHPavoneMEYinPImirGUtsunomiyaHet al. 17beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis. Semin Reprod Med (2010) 28(1):44–50. doi: 10.1055/s-0029-1242992
75
BulunSEChengYHYinPImirGUtsunomiyaHAttarEet al. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol (2006) 248(1-2):94–103. doi: 10.1016/j.mce.2005.11.0411
76
BrosensIBrosensJJBenagianoG. The eutopic endometrium in endometriosis: are the changes of clinical significance? Reprod BioMed Online (2012) 24(5):496–502. doi: 10.1016/j.rbmo.2012.01.022
77
WeiXLiuXTanCMoLWangHPengXet al. Expression and function of zinc-alpha2-glycoprotein. Neurosci Bull (2019) 35(3):540–50. doi: 10.1007/s12264-018-00332-x
78
SeveroJSMoraisJBSBeserraJBDos SantosLRde Sousa MeloSRde SousaGSet al. Role of zinc in zinc-alpha2-glycoprotein metabolism in obesity: A review of literature. Biol Trace Elem Res (2020) 193(1):81–8. doi: 10.1007/s12011-019-01702-w
79
PapukashviliDRcheulishviliNDengY. Beneficial impact of semicarbazide-sensitive amine oxidase inhibition on the potential cytotoxicity of creatine supplementation in type 2 diabetes mellitus. Molecules (2020) 25(9):2029. doi: 10.3390/molecules25092029
80
HassanMIWaheedAYadavSSinghTPAhmadF. Zinc alpha 2-glycoprotein: A multidisciplinary protein. Mol Cancer Res (2008) 6(6):892–906. doi: 10.1158/1541-7786.MCR-07-2195
Summary
Keywords
repeated implantation failure, endometrial receptivity, proteomic, TPPP3, HSD17B2
Citation
Yang J, Wang L, Ma J, Diao L, Chen J, Cheng Y, Yang J and Li L (2023) Endometrial proteomic profile of patients with repeated implantation failure. Front. Endocrinol. 14:1144393. doi: 10.3389/fendo.2023.1144393
Received
14 January 2023
Accepted
13 July 2023
Published
31 July 2023
Volume
14 - 2023
Edited by
Richard Ivell, University of Nottingham, United Kingdom
Reviewed by
Alejandro Tapia-Pizarro, University of Chile, Chile; Youn-Jung Kang, CHA University, Republic of Korea
Updates

Check for updates
Copyright
© 2023 Yang, Wang, Ma, Diao, Chen, Cheng, Yang and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Longfei Li, lilongfei2005@163.com; Jing Yang, dryangjing@whu.edu.cn; Yanxiang Cheng, yanxiangCheng@whu.edu.cn
†These authors have contributed equally to this work
‡These authors share senior authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.